"Challenges and Frustrations Surround RSV Antibody Shot Rollout for Babies"

Pediatricians are facing challenges in obtaining the RSV antibody shot for babies, which has been approved by the CDC and FDA to prevent respiratory syncytial virus in infants. The shot, developed by AstraZeneca and Sanofi, is expected to reduce hospital admissions for RSV in children under 1 year old. However, the lack of infrastructure and high cost of nearly $500 per dose are hindering its rollout. Pediatricians are frustrated and concerned about missed opportunities to protect children from RSV, while insurance companies are focused on the financial aspect. The American Academy of Pediatrics has urged federal leaders to ensure widespread and equitable distribution of the shot.